Novartis Reports Strong Q2 Results, Expects High-Single-Digit Sales Growth
Novartis, a Swiss multinational pharmaceutical company, has reported impressive financial results for the second quarter of 2024. Despite facing challenges, the company expects strong sales growth for the year. Meanwhile, the pharmaceutical industry continues to show resilience amidst market volatility.
Novartis' sales surged by 12% year over year to $14.1 billion in the second quarter, with earnings per share increasing by 23% to $2.42. This remarkable performance was driven by a vast lineup of branded drugs, including 14 blockbusters. The company's CEO, Vasant Narasimhan, has led the company since February 2018.
Despite facing a patent cliff for its heart failure drug Entresto, Novartis anticipates high-single-digit sales growth for the year. This optimism is buoyed by the industry's defensive nature, which tends to perform well even during economic downturns. Equity markets, however, have experienced significant volatility this year due to concerns over aggressive trade policies.
Gilead Sciences, another major player, reported revenue growth of 2% year over year to $7.1 billion, with EPS up 21% to $1.56. The company boasts a forward yield of over 2.8% and has increased its payouts by 83.7% in the past decade. Gilead's leadership in the HIV drug market, with treatments like Biktarvy and Descovy, contributes to its strong performance.
Novartis' robust financial results and positive outlook reflect the pharmaceutical industry's resilience. With a forward yield of 3.2% and 28 consecutive years of dividend increases, Novartis remains an attractive investment. Meanwhile, Gilead Sciences' strong performance and high forward yield make it another compelling option in the sector.
Read also:
- Regensburg Customs Crackdown Nets 40+ Violations in Hotel Industry
- Mural at blast site in CDMX commemorates Alicia Matías, sacrificing life for granddaughter's safety
- Germany Boosts EV Charging: 1,000 Fast-Charging Points on Motorways by 2026
- Albanese Invites LuLu Group to Australia as Free Trade Deal Takes Effect
